Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 12, 2011, Pages 2618-2627

  Dhillon, Preet K ^a,c,e   Penney, Kathryn L ^a   Schumacher, Fredrick ^a,c   Rider, Jennifer R ^a   Sesso, Howard D ^b   Pollak, Michael ^d   Fiorentino, Michelangelo ^c   Finn, Stephen ^c   Loda, Massimo ^c   Rifai, Nader ^f   Mucci, Lorelei A ^a,c   Giovannucci, Edward ^a,c   Stampfer, Meir J ^a,c   Jing, Ma ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; INSULIN RECEPTOR; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER TISSUE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, ADIPONECTIN; RISK FACTORS;

EID: 83055173313     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0434     Document Type: Article

References (35)

1. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007;109:1192-202. (Pubitemid 46435400)
2. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-47.
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9. (Pubitemid 41124175)
4. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005;65:1168-72. (Pubitemid 40824911)
5. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007;16:308-13. (Pubitemid 46383351)
6. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008;68:1592-8.
7. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25 year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010;56:34-43.
8. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006;15:1331-5. (Pubitemid 44125290)
9. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation tomalignancies: a reviewof existing basic research and clinical evidence. Am J Clin Nutr 2007;86:s858-66.
10. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-81. (Pubitemid 38269336)
11. Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005;579:6821-6. (Pubitemid 41773693)
12. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-32. (Pubitemid 30661055)
13. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-9. (Pubitemid 38620209)
14. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004;323:630-5. (Pubitemid 39221142)
15. Wulster-Radcliffe MC, AjuwonKM,WangJ, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004;316:924-9. (Pubitemid 38368041)
16. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340:1158-66. (Pubitemid 43083400)
17. Mistry T, Digby JE, Chen J, Desai KM, Randeva HS. The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun 2006;348:832-8. (Pubitemid 44233495)
18. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 2005;333:79-87. (Pubitemid 40813449)
19. Qi L, Doria A, Manson JE, Meigs JB, Hunter D, Mantzoros CS, et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes 2006;55:1512-6. (Pubitemid 44195395)
20. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002;11:2607-14. (Pubitemid 35174690)
21. Filippi E, Sentinelli F, Romeo S, Arca M, Berni A, Tiberti C, et al. The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels of adiponectin in younger coronary artery disease patients (age < or = 50 years). J Mol Med 2005;83:711-9. (Pubitemid 41225113)
22. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51:536-40. (Pubitemid 34764814)
23. Kaklamani V, Yi N, Zhang K, Sadim M, Offit K, Oddoux C, et al. Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism 2011;60:1234-43.
24. Moore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, et al. Adipokine genes and prostate cancer risk. Int J Cancer 2009;124:869-76.
25. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
26. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II-a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000;10:125-34. (Pubitemid 30089022)
27. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23. (Pubitemid 41568704)
28. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003;49:650-2. (Pubitemid 36379531)
29. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003;361:598-604. (Pubitemid 36207482)
30. Vasseur F, Meyre D, Froguel P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev Mol Med 2006;8:1-12. (Pubitemid 44782612)
31. Beebe-Dimmer JL, Zuhlke KA, Ray AM, Lange EM, Cooney KA. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis 2010;13:362-8.
32. Heid IM, Wagner SA, Gohlke H, et al. Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes 2006;55:375-84. (Pubitemid 43343266)
33. Crimmins NA, Martin LJ. Polymorphisms in adiponectin receptor genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes Rev 2007;8:419-23. (Pubitemid 47283939)
34. Tang CH, Lu ME. Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways. Prostate 2009;69:1781-9.
35. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121:1571-8. (Pubitemid 47328718)